Sawaki Masataka, Muramatsu Yasuaki, Togo Kanae, Laurent Thomas, Iwata Hiroji
Breast Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya-shi, Aichi, 464 8681, Japan.
Oncology Medical Affairs, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151 8589, Japan.
Future Oncol. 2022 Jun;18(17):2101-2111. doi: 10.2217/fon-2021-1448. Epub 2022 Mar 21.
To reveal the treatment patterns of palbociclib and complete blood count (CBC) monitoring in a Japanese real-world setting. Deidentified data of patients with advanced breast cancer who received palbociclib from 2017 to 2020 were examined from a Japanese claims database. We identified 1074 patients. Palbociclib was commonly prescribed as second- or later-line treatment in 2017/2018; thereafter its first-line treatment increased. Regardless of treatment lines, fulvestrant was most commonly prescribed in combination with palbociclib (57-66% in the first-third-line), and this finding differed from that in the USA. Most patients initiated palbociclib at 125 mg/day; however, over a half of patients reduced doses within the first 8 weeks. Although CBC was regularly monitored, some patients did not undergo blood tests. Early dose reduction and CBC monitoring should be performed cautiously to minimize safety concern and prevent early treatment discontinuation.
为揭示在日本真实临床环境中哌柏西利的治疗模式及全血细胞计数（CBC）监测情况。从日本医保数据库中调取了2017年至2020年接受哌柏西利治疗的晚期乳腺癌患者的匿名数据。我们共识别出1074例患者。2017/2018年，哌柏西利通常作为二线或更后线治疗药物开具；此后其一线治疗使用量有所增加。无论治疗线数如何，氟维司群最常与哌柏西利联合使用（一线至三线治疗中占57 - 66%），这一结果与美国的情况不同。大多数患者开始使用哌柏西利的剂量为每日125毫克；然而，超过半数的患者在开始治疗的8周内降低了剂量。尽管定期进行CBC监测，但仍有部分患者未接受血液检测。应谨慎进行早期剂量调整及CBC监测，以尽量减少安全问题并防止过早停药。
